The Pot Report. Get the Report
The week in cannabis, in five minutes.Free, every week, from The Pot Report.
Get the Report

Laws

Laws · November 10, 2026

DEA Boosts Psychedelic Production Quotas For 2027 While Previewing Separate Marijuana Proposal Under Rescheduling

The DEA's 2027 marijuana production quotas will stay at 2026 levels for cannabis left in Schedule I, according to a draft Federal Register notice. The agency wants far more MDMA and ibogaine made for research, plus modest increases for psilocybin and psilocyn. A separate notice will cover rescheduled Schedule III marijuana.

Why it matters: Holding Schedule I marijuana quotas flat means research supply isn't growing, while the real change comes later. Medical cannabis moved to Schedule III still has no federal production figures, and DEA is still registering handlers and gathering data. Patients and buyers should read this as a placeholder: the numbers that matter for rescheduled products are still to come.

Read moreSource: Marijuana Moment

Laws · November 10, 2026

West Hollywood is preserving the untold stories of cannabis legalization

To mark the 30th anniversary of California's Proposition 215, Emerald Village West Hollywood and the LGBTQ heritage non-profit THE LAVENDER EFFECT® launched the West Hollyweed Oral Histories Project to document the city’s early medical cannabis movement. The project debuts with five in-depth video interviews featuring local pioneers, dispensary operators, city officials, and HIV/AIDS activists who recount federal DEA raids, early municipal zoning battles, and the life-saving role of cannabis during the AIDS epidemic. Organizers plan to expand this initial collection into a broader historical archive chronicling cannabis legalization efforts and activism across Southern California.

Why it matters: The West Hollyweed Oral Histories Project to document the city’s early medical cannabis movement.

Read moreSource: GreenState